LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on digital health and artificial intelligence solutions for Latin America, has announced an agreement with DROGUERIAS LALA C.A. to develop AI-supported and automated software tools for pharmaceutical and laboratory operations. The collaboration, facilitated through LataMed AI's Venezuelan subsidiary LATAMEDAI VE, aims to design, develop, test, and evaluate customized technology intended to support workflows in pharmaceutical research, laboratory testing, quality control, documentation, operational coordination, and data analysis.
The proposed technology is expected to include software tools that organize and analyze information generated during pharmaceutical development and laboratory activities. Planned features may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools designed to help qualified personnel identify potential inconsistencies or operational issues at an earlier stage. The parties will begin by identifying specific workflows, defining technical and operational requirements, and establishing a phased development and testing process. They will also set up confidentiality, information-security, data-management, and access-control procedures.
Dr. Kevin Rodan Levy, CEO of LataMed AI, emphasized the importance of responsible technology development: "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
The collaboration could expand LataMed AI's technology into enterprise pharmaceutical and laboratory applications beyond its existing patient-facing telemedicine services. Management believes that, if successfully developed and implemented, the resulting technology may provide a framework adaptable for other organizations in Venezuela and Latin America, though future expansion would depend on separate agreements, successful testing, operational readiness, regulatory requirements, and organizational needs.
Importantly, the technology is designed as a decision-support and workflow-management resource, not as a replacement for professional judgment. It will not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions. All pharmaceutical, scientific, laboratory, and quality-control determinations will remain the responsibility of qualified professionals and regulatory authorities.
The agreement establishes a framework for collaboration but does not guarantee specific implementation schedules, commercial deployment, cost reductions, scientific or regulatory outcomes, revenue, or profitability. The parties will evaluate ownership, licensing, permitted use, and protection of any intellectual property developed through the collaboration, with terms governed by the agreement and additional documentation.
This initiative aligns with LataMed AI's broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, and other healthcare ecosystem participants. The company is also developing AI platforms for cardiovascular, pulmonary, and neurological health, under the names CardioAI, PulmoAI, and NeuroAI, which remain subject to continued development and regulatory approval.
The announcement underscores the growing trend of integrating AI into pharmaceutical and laboratory settings, where it can enhance data analysis, streamline workflows, and support quality control. For the healthcare industry, such collaborations could lead to more efficient operations and improved decision-making, while maintaining necessary professional oversight.
